Closing Before the CCI Says Yes
Alturo NV, a European health insurer with global assets of about Rs 5.2 lakh crore, signed agreements on 5 April 2024 to acquire 100% of MedCare Services Ltd (MSL) for Rs 3,100 crore and 26% of Suraksha Health Insurance Ltd (SHIL) for Rs 1,640 crore, both from a private equity fund. MSL is India's largest third-party administrator, with a 39% share of a market whose HHI is 2,600 and revenue of Rs 1,450 crore. Alturo already holds 49% of ClaimOne India, a competing administrator with a 22% share, but no board seats there. SHIL has gross written premium of Rs 6,800 crore and a 7.2% market share; the 26% stake comes with a shareholders' agreement giving Alturo vetoes over the annual budget, the appointment of the CEO and any change in the business plan. The share purchase agreement is conditional on CCI approval, but the parties plan to appoint two nominee directors to MSL on 1 May 2024 and to go live on a shared IT platform on the same date. IRDAI approval has not been applied for. The general counsel asks whether the deal can close in stages.
1. Is the transaction notifiable to the CCI, and which form should be used? Address the two acquisitions separately and then together.
Read the worked answer
MSL. The acquisition of 100% is a combination under section 5(a) - acquisition of control - and, independently, under section 5(b) if the target thresholds are met. MSL's turnover of Rs 1,450 crore and the group's assets are far above every edition of the threshold notification, so notifiability does not turn on which revision applies. The deal value is also well above the Rs 2,000 crore deal-value threshold, which brings its own substantial-business-operations-in-India test.
SHIL. A 26% stake alone might fall below the target thresholds, but control is the question (see the next task), and if control is acquired section 5(a) applies irrespective of size.
Together. Inter-connected transactions are treated as a single combination under the Combination Regulations. The two acquisitions are signed the same day with the same seller and are commercially linked; splitting them to stay below a threshold is not available.
Form. Form I is intended for combinations with no material overlap. Here the combined third-party administrator share would be 39% + 22% = 61% on an already concentrated market (HHI 2,600), and the horizontal overlap exceeds the 15% guidance for Form I. Form II is the appropriate filing, and the parties should expect a Phase II investigation. Filing Form I to save time would invite a section 20(1) direction to file Form II and lose more time than it saves.
2. Do the SHIL veto rights confer control, and what is the gun-jumping exposure in the plan to appoint nominee directors and share an IT platform on 1 May 2024?
Read the worked answer
Control. Control under the Competition Act is the ability to exercise decisive influence over the affairs or management of an enterprise, and need not be sole control. Vetoes over the annual budget, the appointment of the CEO and any change in the business plan are not ordinary minority protections; they are the levers through which a 26% holder can direct strategy. Read together with 26% and the shareholders' agreement, they are likely to amount to joint control of SHIL and to make the acquisition a combination under section 5(a). The alternative view - that 26% with negative covenants is only material influence and not control - is arguable but not safe to rely on when the veto list is this wide.
Gun-jumping. Section 6(2A) is a standstill: no combination may take effect until CCI approval or expiry of the review period. Appointing two nominee directors to MSL and going live on a shared IT platform before approval is consummation in substance, whatever the SPA says about conditions precedent. Exposure is a penalty under section 43A of up to 1% of the combined assets or turnover of the combination, whichever is higher - a very large number given Alturo's balance sheet - and the CCI has increasingly treated board seats and integration of operations as the clearest evidence of gun-jumping.
Staging. The deal can be signed and can be economically protected through earn-outs, deposits and interim covenants, but the parties must not exercise influence. Nominee directors should be appointed only after approval or expiry of the clock, and the IT integration should be ring-fenced on a transitional-services basis with no transfer of customer data or pricing decisions.
3. What sectoral approvals are required, and how do they interact with the competition review and the transaction timetable?
Read the worked answer
Insurance. Acquisition of 5% or more of the paid-up capital of an insurer requires prior approval of IRDAI under the Insurance Act, 1938. The transaction must also satisfy the foreign investment regime: the sectoral cap for insurance is 74%, with Indian ownership and control conditions, and a proposal to raise it to 100% announced in the Union Budget 2025-26 that still requires legislative amendment. A 26% stake in an Indian insurer held by a foreign group will be tested for fit-and-proper status of the acquirer, the source of funds, and the governance arrangements. The veto rights that make the deal attractive for Alturo are precisely what the regulator will scrutinise against the Indian-owned-and-controlled requirement.
TPA. MSL is regulated by IRDAI as a third-party administrator; a change of control also requires IRDAI's approval and a fresh registration or amendment. The shared IT platform raises outsourcing and data-localisation questions that IRDAI will examine.
Sequencing. The two regimes are not alternatives. CCI approval does not substitute for IRDAI approval, and an IRDAI approval obtained without CCI clearance cannot be acted upon. The practical sequence is: file Form II immediately after signing, run the IRDAI application in parallel (it is typically the longer of the two), avoid any step that could be characterised as consummation, and build the long-stop date around the slower of the two approvals rather than the 150-day competition clock.